Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

EF Hutton Reiterates Hold on TCR2 Therapeutics, Maintains $2 Price Target

Author: Benzinga Newsdesk | March 23, 2023 09:25am
EF Hutton analyst Tony Butler reiterates TCR2 Therapeutics (NASDAQ:TCRR) with a Hold and maintains $2 price target.

Posted In: TCRR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist